PDSB PDS Biotechnology
- 3.510
- -0.320-8.36%
- 3.550
- +0.040+1.14%
PDS Biotechnology News
PDS Biotechnology Says Head, Neck Cancer Therapy Met Main Goal in Mid-Stage Study
PDS Biotechnology (PDSB) said late Thursday its experimental therapy to treat a type of head and neck cancer in combination with Merck's Keytruda met the primary study endpoints in a phase 2 clinical
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
30 month median overall survival (OS); median OS independent of patient CPS score ORR 34% (CPS≥1); 48% (CPS≥20) Phase 3 registrational trial planned to initiate in 2024 PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE)
HC Wainwright & Co. : The PDS Biotechnology (PDSB.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $21.00.
HC Wainwright & Co. : The PDS Biotechnology (PDSB.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $21.00.
HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates PDS Biotechnology with a Buy and maintains $21 price target.
Cantor Fitzgerald Reiterates Overweight on PDS Biotechnology
Cantor Fitzgerald analyst Louise Chen reiterates PDS Biotechnology (NASDAQ:PDSB) with a Overweight.
PDS Biotech to Participate in Upcoming May 2024 Investor Conferences
PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets
Buy Rating Affirmed on PDS Biotechnology's Promising HNSCC Treatment Developments
PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024
PRINCETON, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets
PDS Biotechnology Announces Details of Virtual KOL Event
PRINCETON, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets
PDS Biotech: Toutain's Appointment Effective From May 1 >PDSB
PDS Biotech: Toutain's Appointment Effective From May 1 >PDSB
PDS Biotechnology Welcomes Stephan Toutain as New COO
PDS Biotech To Event To Discuss Positive, Updated Data From Phase 2 VERSATILE-002 Clinical Trial With Versamune HPV In Combination With KEYTRUDA In Recurrent Or Metastatic Head And Neck Cancer
Company to Host Key Opinion Leader Event on May 8 at 1:30pm ET to Discuss Updated Results of VERSATILE-002, Unmet Treatment Needs in Advanced Head and Neck Cancer and planned Triple Combination Trial
PDS Biotechnology Corporation's (NASDAQ:PDSB) Market Cap Dropped US$1.5m Last Week; Individual Investors Who Hold 59% Were Hit as Were Institutions
PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2023 Earnings Call Transcript
Noble Financial Sticks to Its Buy Rating for PDS Biotechnology (PDSB)
B. Riley Securities Adjusts PDS Biotechnology's Price Target to $11 From $14, Maintains Buy Rating
B. Riley Securities Adjusts PDS Biotechnology's Price Target to $11 From $14, Maintains Buy Rating.
PDS Biotechnology: Strategic Shift to Triplet Therapy Promises Enhanced Clinical Success
Q4 2023 PDS Biotechnology Corp Earnings Call
Earnings Call Summary | PDS Biotechnology(PDSB.US) Q4 2023 Earnings Conference
The following is a summary of the PDS Biotechnology Corporation (PDSB) Q4 2023 Earnings Call Transcript:Financial Performance:PDS Biotechnology Corporation reported a net loss of approximately $42.9 m
PDS Biotechnology: A Strong Buy on Strategic Focus and Promising HNSCC Trial Data
Analysis
Price Target
No Data
